Dialectic Medicine
Behavioral intervention has limited benefits because it doesn't address how patients think about their clinical decisions.
DEA Sets CDC Opioid Guidelines
The CDC unveiled its latest opioid prescribing guidelines. It's decidedly more patient centric, but fails to account for how law...
Declare Pandemic Uncertainty
Enough time has passed to where we are reflecting on the pandemic for a sense of closure. We would be...
Arc of Medicare Advantage Plans
Medicare Advantage plans are facing scrutiny after years of excessive billing practices. The fraud exemplifies how delivery models cannot align...
HIPAA Hinders Gun Advocacy
HIPAA was designed to protect patient rights. But for victims of gun violence and the advocates who help them, it...
Biased Coverage of Gun Violence
Journalists often portray gun violence through familiar patterns of writing. This format misrepresents the full story of those involved.
Gun Violence Data Lacks Meaning
Gun violence data may appear startling, but they lack meaningful context. It would help to correlate the statistics with broader...
Administrative Acts of Healthcare Crime
The FDA has asked the DOJ for support in issuing its first ever injunction against six vaping manufacturers.
Thinking About Viruses
Viruses are acting differently. It's clear the pandemic altered the virosphere in unknown ways, with consequences yet to emerge.
Social Determinants of Venture Capital
Venture capital firms are pouring lavish sums into environmental health. Will there be a return on investment?
To be a Physician Influencer
Many physicians have become social media influencers. Their online presence has altered the patient relationship in ways we have yet...
Mining Medical Noise
We're familiar with online misinformation. But we’re less familiar with how information overload affects our judgment. It’s time to study...
FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation
Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...
Read more